Autobio Diagnostics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Zeng Li Yang

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Zeng Li Yang (56 yo)

no data

Mandato

CN¥722,500

Compensazione

Mr. Zeng Li Yang served as Deputy General Manager at Autobio Diagnostics Co., Ltd. and has been its Supervisors Director since 2003. Mr. Yang has been Vice president at National Health Industry Enterprise...

Autobio Diagnostics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Autobio Diagnostics Co., Ltd., Annual General Meeting, May 09, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.56 (vs CN¥0.61 in 3Q 2023)

Investor sentiment improves as stock rises 26%

Autobio Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.53 (vs CN¥0.52 in 2Q 2023)

Autobio Diagnostics Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024

Autobio Diagnostics Co., Ltd., Annual General Meeting, May 09, 2024

First quarter 2024 earnings released: EPS: CN¥0.56 (vs CN¥0.42 in 1Q 2023)

Autobio Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024

Investor sentiment improves as stock rises 16%

Autobio Diagnostics Co., Ltd. (SHSE:603658) announces an Equity Buyback for CNY 500 million worth of its shares.

Autobio Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.61 (vs CN¥0.63 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.50 in 2Q 2022)

Autobio Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: EPS: CN¥0.42 (vs CN¥0.41 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.63 (vs CN¥0.52 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.50 (vs CN¥0.41 in 2Q 2021)

Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped from S&P Global BMI Index

Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped from S&P Global BMI Index

Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped from FTSE All-World Index (USD)

First quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.29 in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.52 (vs CN¥0.43 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.32 in 2Q 2020)

Investor sentiment improved over the past week

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Mobidiag Oy from Autobio Diagnostics Co., Ltd. (SHSE:603658) and others for an enterprise value of approximately $810 million

First quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.22 in 1Q 2020)

New 90-day low: CN¥122

New 90-day low: CN¥132

New 90-day low: CN¥141

New 90-day low: CN¥145

Third quarter earnings released

New 90-day high: CN¥174

Autobio Diagnostics Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high: CN¥169

First half earnings released

Autobio Diagnostics Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione